
I Alnylam Pharmaceuticals

Focused on Developing RNAi Therapeutics

Alnylam is a biopharmaceutical company leading the development of RNA interference (RNAi) therapeutics. The discovery of RNAi has been heralded as a major scientific breakthrough, and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today.

RNAi is a natural mechanism of gene silencing that occurs in organisms ranging from plants to mammals. RNAi therapeutics in development have the potential to treat diverse disease states and help patients in a fundamentally new way.



Investigational RNAi Therapeutics

Active Product Pipeline and Experience to Date

RNAi therapeutics in development by Alnylam are engineered to enable a consistent level of target knockdown. Alnylam's pipeline of investigational RNAi therapeutics is currently focused in four Strategic Therapeutic Areas (STArs): **Genetic Medicines**, **Cardio-Metabolic Diseases**, **Infectious Disease**, **and CNS/Ocular Diseases** - **and we are actively exploring other disease areas**.



* As of April 2025 across all active programs. Numbers are approximate as many studies are ongoing and several are blinded.

To learn more about Alnylam and our pipeline advancements, please visit Alnylam.com

Our Pipeline

International Internatione International International International International			PHASE 1	PHASE 2	PHASE 3	COMMERCIAL
Number All II Ampledates with Underweterky (M) Keessian ATTR Ampledates with Underweterky (M) Keessian ATTR Ampledates with Underweterky (M) Keessian Attra Ampledates Circle Kee	ONPATTRO ®	hATTR Amyloidosis with Polyneuropathy (PN)		_		
Number AttR Visitizing ATtR Ampliants with Castelemystele (CA) Number of the Castelemystele (CA) AttR Ampliants with Castelemystele (CA) State Handson AttR Ampliants with Castelemystele (CA) State Handson Premary hypothesis (Tastel (Parky Hand) State Handson Matter Handson (Tastel (Parky Hand) State Handson Matter Hand) State Handson Matter Hand) State Handson (Tastel (Parky Hand) Matter Hand) State Handson (Tastel (Parky Hand) Matter Hand) State Hand (Parky	AMVUTTRA®			_		
Number ATR Ampletess Constrained Acta Header Carphylia (All1) Quantitationed Minary Happenstaria (All1) Quantitationed Minary Happenstaria (Signatura) Parasiana Marathana Carrai Constrained Marathana Constrained Marathananana Constrained						
CALLENTING Print regulation CALLANG* Accoll regulation Type (1999) CALLANG* Print regulation Type (1999) Callandian Print regulation Type (1999) Canadiana Print regulation						
GWARN Acada Hapada Capabyla (Mell) Image Application (Mell) GWARN Hamaphilid Image Application (Mell) Flueiann Hamaphilid Image Application (Mell) GWARN Hamaphilid Image Application (Mell)	(ALN-TTRsc04)	AT IR Amyioidosis				
General Control Manage Manage Manage Manage Manage General Control Manage Manage Manage Function Herropolitik Function Manage Manage Manage General Control Manage Manage Control Manage Manage Control Manage Manage Control Manage Manage Control Manage Manage Manage Manage Control Manage Manage Manage Manage Manage Man					_	
Concession Marginal Index (1970) Flexa in the population of the state of the stat	(givosiran)					
Conditions (r.M. administic) Matchend Grandsi Marganeit Redurand Herengeberunist ALN-4500 Bleding Granders Conditions (r.M. administic) Marganeit Redurand Herengeberunist All-4324 Marganeit Redurand Herengeberunist All-4325 Type 2 Dadvetes Mellina All-4326 Type 2 Dadvetes Mellina All-4327 Type 2 Dadvetes Mellina All-4328 Type 2 Dadvetes Mellina All-4329 Marganeit Redurand Merengebrunist (r.A.) Markandrin Musconfin All-Martrid S Baseas All-Martrid Z Marganeit Redurand Administ (r.M. adming	(lumasiran)	Primary Hyperoxaluria Type 1 (PH1)				
(r). Handbox Market and Market and Henrigkbanula' Image: Condition of the set of t	Fitusiran	Hemophilia ¹				
C F Namesh Falsary and Frank Schuler Her Regulations A LH - 400 Beeding Disorders C A LASS SY ACCULAN Hyperchalasteralering** C A Lass Sy ACCULAN Hyperchalasteralering** Z Liebesian Hyperchalasteralering** Z Liebesian - Kay Lass Hasson Z Liebesian Lasson Hyperchalasteralering** Z Liebesian Alw Hord C, Falty Law Disease (ALR)D* Z Liebesian Alw Hord C, Falty Law Lasson K (ALS)* Z Liebesian Alw Hord C, Falty Law Lasson K (ALS)* Z Liebesian Alw Hord C, Alwy Hy K Z Liebesian Central Arrylout Anoptophic Lateral Scherols (ALS)* Z Liebesian Hasatis B Virus Infection* Z Liebesian Hasatis B Virus I	Cemdisiran (+/- Pozelimab)	Myasthenia Gravis ¹				
CATOLICY CLAIN Exclusion Mynetcholesterolemial Ziebesiran Mynetcholesterolemial Katabolic Cycluscion-Associated Ministriki (MASH) ALN-432A Type 2 Daabetes Meditas ALN-452A Type 2 Daabetes (MAE,D)* ALN-452A Type 2 Daabetes (MAE,D)* ALN-APPR Non-Alcohelic faity Liver Disease (NAE,D)* Minebiran Alphiner's Disease Minebiran Alphiner's Disease ALN-SOD SoD Amyelonghy (CAA) Minebiran Conferal Amyloid Anglopathy (CAA) Minebiran Alphiner's Disease* ALN-SOD SoD Amyelonghy Virtue Conferal Ministrik (Mash)* Kurterionan Conferal Amyloid Anglopathy (CAA) Ministrian Conferal Amyloid Anglopathy (CAA) Ministrian Conferal Amyloid Anglopathy (CAA) Minitre Confinan <th>Cemdisiran (+ Pozelimab)</th> <th>Paroxysmal Nocturnal Hemoglobinuria¹</th> <th></th> <th></th> <th></th> <th></th>	Cemdisiran (+ Pozelimab)	Paroxysmal Nocturnal Hemoglobinuria ¹				
Lebsina Hypercholesterolemia ¹⁰ Image: Constraint of the series of	ALN-6400	Bleeding Disorders				
Circletarian() Optimized Circletarian() Zilebesiran Hypertension ² Zilebesiran excession Hypertension ² Hypertension ² Hypertension ² Responsion Metabolic Dynfunction-Associated Silebesiran (MARLAN) ALN-AS24 Type 2 Diabetes Melitus ALN-APPC Non-Acholic fatty Liver Disease (NAFLD) ALN-APPC Dysleptension ² Metabolic Conference Conference Microsociated Silebesiran (MARLAN) ALN-APPC Dysleptension ² ALN-APPC Dysleptension ² Metabolic fatty Liver Disease (NAFLD) Conference ALN-APPC Dysleptension ² Microsociated Conference Circle Conference Conference Microsociated Conference Conference Conference Conference Conference Conference Conference Conference Conference Conference Conference C	CARDIOVASCULAR					
Zilebesiran - REVERSIR Hypertension ⁴ Regionsian Revenue Metabolic Dysfunction-Associated Statuhespits (MASH ⁰) ALN-432.4 Type 2 Diabetes Mellitus ALN-432.4 Type 2 Diabetes Mellitus ALN-432.4 Type 2 Diabetes Mellitus ALN-APOC3 Dysfuidemia ⁴ Metabolic Fatty Liver Disease (NARLD) ⁴ Image: Constraint of the co	Leqvio [®] (inclisiran)	Hypercholesterolemia ¹				
Mitabolic Dysfunction-Associated Autwention Metabolic Dysfunction-Associated Selective attrins (MASH) ALN-4324 Type 2 Diabetes Mellitus ALN-4324 Type 2 Diabetes Mellitus ALN-APPP Non-Alcoholic Fatty Liver Disease (NAFLD) ¹ ALN-APOC3 Dyslip idemia ¹ Multison Dyslip idemia ¹ Multison Cerebral Amyloid Angiopathy (CAA) Multison Altheimer's Disease ALN-APOC3 SoDi Amyloid Angiopathy (CAA) Multison Altheimer's Disease ALN-APOC3 SoDi Amyloid Angiopathy (CAA) Multison SoDi Amyloid Angiopathy (CAA) Multison SoDi Amyloid Ingiopathy (CAA) Multison Hopatitison (Multison (M	Zilebesiran	Hypertension ²				
Reginsing ULBABOIC Dysfunction-Associated Steatchepatits (MASHY) Image: Control of Con	Zilebesiran + REVERSIR	Hypertension ²				
Repriserian (ML+490) Metabolic Dysfunction-Associated Steatohepatitis (MASH) ALN-4324 Type 2 Diabetes Mellitus Image: Company of the Com						
ALN-4324 Type 2 Diabetes Mellitus Image: Control of Control of Control Diabase (NAFLD)* Image: Control Diabase (NAFLD)* ALN-APOC3 Dyslipidemia* Image: Control Diabase (NAFLD)* Image: Control Diabase (NAFLD)* KURN-COSC Image: Control Diabase (NAFLD)* Image: Control Diabase (NAFLD)* Image: Control Diabase (NAFLD)* Muse Signan Cenebral Amyloid Angiopathy (CAA) Image: Control Diabase Image: Control Diabase ALN-HTT02 Huntington's Disease* Image: Control Diabase Image: Control Diabase ALN-SOD SOD1 Amyloing Diabase* Image: Control Diabase Image: Control Diabase Crete Control Diabase* Image: Control Diabase Image: Control Diabase Crete Control Diabase* Image: Control Diabase Image: Control Diabase Crete Control Diabase* Image: Control Diabase Image: Control Diabase Crete Control Diabase Image: Control Diabase Image: Control Diabase Crete Control Diabase Image: Control Diabase Image: Control Diabase Crete Control Diabase Image: Control Diabase Image: Control Diabase Crete Control Diabase Image: Control Diabase Image	Rapirosiran					
ALN-APOC3 Dyslipidemia' NUELSIGAD Everbal Amyloid Angiopathy (CAA) Mixelsiran (ALN-AP) Alzheimer's Disease ALN-HTT02 Huntington's Disease* ALN-SOD SODI Amyotrophic Lateral Sclerosis (ALS)* OTHER Everbalization Ecensionan (ALN-HBV02/VIR-228) Geographic Atrophy* Hepatitis D Virus Infection* Everbalization						
NEUROLOGIC Mive/siran (ALN-APP) Cerebral Amyloid Angiopathy (CAA) Mive/siran (ALN-APP) Alzheimer's Disease ALN-HTTO2 Huntington's Disease ⁴ ALN-SOD SOD1 Amyotrophic Lateral Sclerosis (ALS) ^a OTHEE Elebsiran (ALN-HPV02/VIR-2218) Geographic Atrophy ¹ Image: Hepatitis D Virus Infection ⁵ Hepatitis D Virus Infection ⁵	ALN-PNP	Non-Alcoholic Fatty Liver Disease (NAFLD) ³				
Mivelsiran (LN-APP) Cerebral Amyloid Angiopathy (CAA) Mivelsiran (LN-APP) Alzheimer's Disease ALN-HTTO2 Huntington's Disease ⁴ ALN-SOD SOD1 Amyotrophic Lateral Sclerosis (ALS) ³ OTHEE Ceredisiran (LN-HBV02/VIR-2218) Geographic Atrophy ⁴ Hepatitis B Virus Infection ⁵ Hepatitis D Virus Infection ⁵	ALN-APOC3	Dyslipidemia ¹				
Mivelsiran (AN-APP) Cerebral Amyloid Angiopathy (CAA) Image: Carebral Amyloid Angiopathy (CAA) Mivelsiran (AN-APP) Alzheimer's Disease Image: Carebral Amyloid Angiopathy (CAA) ALN-HTTO2 Huntigton's Disease ⁴ Image: Carebral Amyloid Angiopathy (CAA) ALN-SOD SOD1 Amyotrophic Lateral Sclerosis (ALS) ³ Image: Carebral Amyloid Angiopathy OTHER Image: Carebral Amyloid Angiopathy Image: Carebral Amyloid Angiopathy Elebsiran (AN-HBVOZ/VIR-22IB) Repatitis B Virus Infection ⁵ Image: Carebral Amyloid Angiopathy						
Mixelsiran Alzheimer's Disease ALN-HTTO2 Huntington's Disease ⁴ ALN-SOD SOD1 Amyotrophic Lateral Sclerosis (ALS) ³	Mivelsiran	Cerebral Amyloid Angiopathy (CAA)				
ALN-HTTO2 Huntington's Disease ⁴ Image: Comparison of the	Mivelsiran					
ALN-SOD SODI Amyotrophic Lateral Sclerosis (ALS) ³ OTHER Cendisiran Geographic Atrophy ¹ Geographic Atrophy ¹ Lebsiran Hepatitis B Virus Infection ⁵ Image: Construction Constru						
OTHER Cemdisiran (x/v * Fozelmab) Geographic Atrophy ^a Elebsiran (ALN +BV02/VIR-2218) Hepatitis B Virus Infection ⁵ Elebsiran (ALN +BV02/VIR-2218) Hepatitis D Virus Infection ⁵						
Cemdisiran (+/- Pozelimab) Geographic Atrophy ³ Elebsiran (ALN-HBV02/VIR-2218) Hepatitis B Virus Infection ⁵ Elebsiran (ALN-HBV02/VIR-2218) Hepatitis D Virus Infection ⁵						
Elebsiran (ALN-HBV02/VIR-2218) Hepatitis B Virus Infection ⁵ Elebsiran (ALN-HBV02/VIR-2218) Hepatitis D Virus Infection ⁵						
C(ALN-HBV02/VIR-2218) Hepatitis D Virus Infection ⁵ Elebsiran (ALN-HBV02/VIR-2218) Hepatitis D Virus Infection ⁵		Geographic Atrophy ¹				
	(ALN-HBV02/VIR-2218)	Hepatitis B Virus Infection ⁵				
ALN-BCAT Hepatocellular Carcinoma	Elebsiran (ALN-HBV02/VIR-2218)	Hepatitis D Virus Infection ⁵				
	ALN-BCAT	Hepatocellular Carcinoma				
ALN-ANG3 Healthy Volunteers'	ALN-ANG3	Healthy Volunteers1				

Out-licensed with milestones and/or royalties Partnered, Alnylam-led development with US profit split and milestones/royalties ex-US

Partner-led with profit split
 Partnered, Alnylam-led with profit split
 Partner-led with Alnylam option for profit split

Alnylam Clinical Development Pipeline as of February 2025